%0 Journal Article
%T Revisiting of cancer vaccine?¡ªSpecific immunotherapy comes to field with the biomarker
%A Hiroyuki Suzuki
%A Mitsunori Higuchi
%A Satoshi Muto
%A Takeo Hasegawa
%A Yuki Owada
%J Archive of "Annals of Translational Medicine".
%D 2016
%R 10.21037/atm.2016.04.17
%X Coley et al., advocated a hypothesis of immune response against malignant tumors and he applied his concept by providing patients with the first cancer immunotherapy in 1906 (1). A few decades later, Bacillus Calmette-Guerin was introduced as a tumor immunotherapy by Old et al. (2). These non-specific immunotherapies have been promising cancer therapies, however, they were not widely accepted because of the unstable efficacy and a lack of understanding of the mechanisms of action. After understanding tumor-associated antigens and after discovering dendritic cells, the cancer immunotherapies primarily studied were specific cancer immunotherapies, such as cancer vaccines and dendritic cell vaccines
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876275/